Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1990 1
1992 1
1994 2
1995 1
1996 2
1999 1
2000 1
2001 1
2002 1
2003 2
2004 1
2005 2
2007 1
2010 4
2011 2
2012 3
2013 2
2014 1
2015 2
2016 3
2017 2
2019 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Mitosis in Cancer: Emerging Strategies.
Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW. Dominguez-Brauer C, et al. Among authors: bray mr. Mol Cell. 2015 Nov 19;60(4):524-36. doi: 10.1016/j.molcel.2015.11.006. Mol Cell. 2015. PMID: 26590712 Free article. Review.
Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Kubli SP, Vornholz L, Duncan G, Zhou W, Ramachandran P, Fortin J, Cox M, Han S, Nechanitzky R, Nechanitzky D, Snow BE, Jones L, Li WY, Haight J, Wakeham A, Bray MR, Mak TW. Kubli SP, et al. Among authors: bray mr. Nat Commun. 2019 Jun 18;10(1):2678. doi: 10.1038/s41467-019-10619-w. Nat Commun. 2019. PMID: 31213601 Free PMC article.
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Kubli SP, Vornholz L, Duncan G, Zhou W, Ramachandran P, Fortin J, Cox M, Han S, Nechanitzky R, Nechanitzky D, Snow BE, Jones L, Li WY, Haight J, Wakeham A, Bray MR, Mak TW. Kubli SP, et al. Among authors: bray mr. Nat Commun. 2019 Sep 3;10(1):4069. doi: 10.1038/s41467-019-12106-8. Nat Commun. 2019. PMID: 31481706 Free PMC article.
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.
Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Plotnikova O, Awrey DE, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Fletcher GC, Mak TW, Bray MR, Pauls HW. Liu Y, et al. Among authors: bray mr. ACS Med Chem Lett. 2016 May 6;7(7):671-5. doi: 10.1021/acsmedchemlett.5b00485. eCollection 2016 Jul 14. ACS Med Chem Lett. 2016. PMID: 27437075 Free PMC article.
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL. Veitch ZW, et al. Among authors: bray mr. Br J Cancer. 2019 Aug;121(4):318-324. doi: 10.1038/s41416-019-0517-3. Epub 2019 Jul 15. Br J Cancer. 2019. PMID: 31303643 Free PMC article. Clinical Trial.
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y, Lang Y, Patel NK, Ng G, Laufer R, Li SW, Edwards L, Forrest B, Sampson PB, Feher M, Ban F, Awrey DE, Beletskaya I, Mao G, Hodgson R, Plotnikova O, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW. Liu Y, et al. Among authors: bray mr. J Med Chem. 2015 Apr 23;58(8):3366-92. doi: 10.1021/jm501740a. Epub 2015 Apr 3. J Med Chem. 2015. PMID: 25763473
36 results